Mushrooms and Brain Activity: Series Overview

Project Description

#

The “Mushrooms and Brain Activity” series is a large-scale OSINT investigation into the effects of mushrooms on cognitive function, mental health, and human well-being. The research was conducted within FolkUp Research Lab (Lucerna).

Goal: An objective, in-depth analysis — from neuropharmacology to cultural myths, from clinical data to marketing manipulation. Critical approach: facts, not hype.

Methodology: OSINT (Open Source Intelligence) — systematic collection, verification, and analysis of open sources. Every claim is marked with an evidence level. Conflicts of interest among researchers are identified and documented.

Series Structure (10 Materials)

#

Direction 1: Neuropharmacology

#

Direction 2: Ethnobotany and Toxicology

#

Direction 3: Industry and Myths

#

Key Findings

#

1. Lion’s Mane (Hericium erinaceus)

#

• NGF stimulation in vitro: confirmed (erinacines and hericenones)
• Cognitive improvements in humans: contradictory data, small samples (n=30-41), short-term studies
• Marketing claims (“boost memory”): not confirmed by RCTs
• Doar et al. (2025): erinacines concentrate in mycelium, not in fruiting body; substrate affects biosynthesis

2. Psilocybin

#

• Full-dose therapy (25 mg+): strong evidence for treatment-resistant depression and end-of-life anxiety
• FDA Breakthrough Therapy Designation (2018) — approval expected ~2026-2027
• Microdosing: most likely placebo — largest RCT (Imperial College, n=191) found no difference between microdose and placebo
• Activated Expectancy Bias (AEB): explains self-reported benefits of microdosing

3. Amanita muscaria (Fly Agaric)

#

• Pharmacology: ibotenic acid (NMDA agonist, neurotoxic) + muscimol (GABA-A agonist, sedative)
• Dosage unpredictable: variability up to 10× between specimens
• Lethality: extremely rare with modern medicine, but poisonings are painful
• Contemporary trend: Amanita microdosing (legal in most countries) — no RCTs

4. Castaneda and Ethnobotany

#

• Academic critique: de Mille (1976-1980) convincingly demonstrated fabrications
• Biopiracy: modern ethics require informed consent and benefit-sharing (Nagoya Protocol)
• Entheogens: term replaced “psychedelics” in academic discourse

5. Industry and Biohacking

#

• Functional mushrooms market: $10+ billion (2025), 8-10% annual growth
• DSHEA (1994): lack of pre-market approval = 80,000+ supplements without proven efficacy
• EFSA rejected ALL health claims for beta-glucans from mushrooms
• Conflict of interest: Paul Stamets = researcher + Host Defense owner + patent holder

6. Myths

#

• “Lenin is a Mushroom” (Kuryokhin, 1991): brilliant media hoax, first viral hoax on Soviet TV
• Stoned Ape Theory (McKenna): unfalsifiable, no evidence
• Soma = fly agaric (Wasson, 1968): interesting hypothesis, not proven
• Santa = shaman with fly agaric: debunked by Sámi scholars

Safety Markers

#

The series uses a marker system:

• ☠️ TOXIC — substance/combination with high life-threatening risk
• ⚠️ WARNING — significant risk, caution required
• [UNVERIFIED] — claim not confirmed by RCTs
• [FOLKLORE] — traditional knowledge without scientific basis
• [MARKETING] — commercial claim ahead of science

Recommendations for Informed Consumers

#

1. Demand RCTs, not testimonials
2. Check conflicts of interest of researchers
3. Look for third-party testing (COA, HPLC) for supplements
4. Skeptically evaluate miracle claims
5. Consult with a physician before taking any supplements
6. Remember: “clinically proven” ≠ FDA/EFSA approved

Metadata

#

• Investigation ID: INV-031
• Date: 02.03.2026
• Language: English (translation)
• Total volume: ~27,000 words, 10 materials
• Sources: 230+
• Directions: neuropharmacology, ethnobotany, toxicology, industry, mythology, source audit
• Starting point: PubMed 40181478 (Doar et al. 2025, Fungal Biology and Biotechnology)

FolkUp Research Lab | Lucerna